PDI deal deploys 300 sales reps

PDI signed a deal with an undisclosed major pharmaceutical company to employ 300 sales reps and is expected to reap $35–$40 million, the contract sales force provider said.

The contract followed the April termination of the firm's agreement with AstraZeneca, which affected approximately 800 field reps and had a projected $60–$70 million impact.

“This particular ‘major pharmaceutical company' was not necessarily in the market for additional representatives but when they saw the fact that we had some reps trained in a specific category, the light bulb went off and they thought, ‘hey, we could use those people,'” said Stephen Cotugno, PDI EVP of corporate development.

You must be a registered member of MMM to post a comment.

Next Article in Pharmaceutical


Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.